BCMA chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of multiple myeloma. Two industrial BCMA CAR T-cell therapies, Idecabtagene vicleucel, and ciltacabtagene autoleucel, have been approved for use. These therapies have demonstrated unprecedented clinical efficacy, with progression-free survival exceeding the expected 3-4 months in relapsed or refractory multiple myeloma. A new study conducted in Spain by an academic group called ARI0002h has shown that in-house production of CAR T cells in an academic setting is feasible and produces high-quality products with potent activity. This study included 30 patients with relapsed or refractory multiple myeloma, all of whom responded positively to the treatment. After a median follow-up of 18 months, 67% of patients achieved a complete response or better. The median progression-free survival was 14.5 months. These findings highlight the potential of academic-based CAR T-cell therapy production and its ability to deliver positive outcomes for patients with multiple myeloma.

To know more: About the original article click here.